The James Lind Alliance Priority Setting Partnership for Problematic Menstrual Bleeding wants to hear from people with lived experience, their parents/carers and healthcare professionals to set research priorities in this neglected area of women’s health. The survey opens today, Wednesday 5 February, and it will be live until the beginning of April. If you would [...]
Astellas Pharma Ltd in agreement with the Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a statement about Veoza (fezolinetant), highlighting a risk of drug-induced liver injury and new recommendations on the monitoring of liver function before and during treatment. The full statement is available here.
New FAQ document – Joint Guideline on management of unscheduled bleeding on HRT To support healthcare professionals with the implementation of the BMS, BSGE, BGCS, FSRH, GIRFT, RCGP and RCOG joint guideline on the management of unscheduled bleeding on HRT, the Lead Authors, together with colleagues in the NHS Faster Diagnosis Programme Team, have [...]
We are pleased to highlight two new patient information leaflets available on the WHC website. Menopause and kidney disease Produced by Kidney Care UK, this patient information leaflet is for women with chronic kidney disease (CKD). It explains how CKD can affect women as they go through the menopause and the symptoms they may [...]
Premature Ovarian Insufficiency (POI) presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include negative impacts on quality of life, fertility, bone health, cardiovascular function and cognitive health. Although hormone replacement therapy (HRT) can mitigate some of these effects, significant questions remain about the optimal management [...]
The British Menopause Society has published the following response to a new study published in The BMJ: Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial Randomised controlled trials are the gold standard – they match participant demographics to ensure that outcomes are genuinely related to the [...]
We are very pleased to announce the publication of a new BMS Tool for Clinicians – Management of menopause for women with cardiovascular disease. We would like to offer our thanks to the Scottish Government Women’s Health and Heart Health policy teams and the many clinicians who helped to prepare this document, in collaboration with the [...]
The publication today of the reviewed NICE guideline Menopause: identification and management (NG23) marks an important development in the diagnosis and treatment of menopausal women. It builds selectively on the conclusions and recommendations of the original guideline published in November 2015. In the intervening nine years the awareness within the medical profession of the [...]
In the weeks following the BBC One Panorama programme, “The Menopause Industry Uncovered”, which focused on the commercialisation of menopause and exposed the vulnerability of women experiencing menopausal symptoms, the BMS has been contacted by many women regarding their HRT treatment. Some women are now being advised to come off HRT or their HRT [...]
A new survey by the British Menopause Society (BMS) for World Menopause Day confirms many healthcare professionals (HCPs) believe that they do not have access to sufficient evidence-based menopause education and training.* The survey also shows that an increasing number of women are seeking support from HCPs through their menopause transition, but that they [...]
